Novo Nordisk A/S (NYSE:NVO) Shares Bought by Savvy Advisors Inc.

Savvy Advisors Inc. grew its stake in Novo Nordisk A/S (NYSE:NVO) by 91.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 7,123 shares of the company’s stock after purchasing an additional 3,395 shares during the period. Savvy Advisors Inc.’s holdings in Novo Nordisk A/S were worth $613,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of NVO. GQG Partners LLC boosted its stake in Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock valued at $1,117,790,000 after acquiring an additional 5,556,460 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $404,910,000. Loomis Sayles & Co. L P boosted its position in shares of Novo Nordisk A/S by 34.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock valued at $995,397,000 after purchasing an additional 2,947,771 shares during the period. Clearbridge Investments LLC grew its stake in Novo Nordisk A/S by 59.8% during the 4th quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company’s stock worth $368,451,000 after buying an additional 1,602,549 shares during the last quarter. Finally, Sustainable Growth Advisers LP increased its position in Novo Nordisk A/S by 23.6% during the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company’s stock worth $459,416,000 after buying an additional 1,021,498 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on NVO. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 7th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Finally, UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Up 5.8 %

NVO opened at $64.76 on Monday. The business has a 50 day simple moving average of $77.87 and a 200-day simple moving average of $93.34. Novo Nordisk A/S has a 12 month low of $59.32 and a 12 month high of $148.15. The stock has a market capitalization of $290.59 billion, a P/E ratio of 19.68, a P/E/G ratio of 0.90 and a beta of 0.61. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were given a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend was Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 49.54%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.